The success of an Industry Sponsored Research (ISR) depends upon choosing the right country to conduct clinical trials. Speed, quality and reliability are essential criteria for a site to be awarded the study. Malaysia offers a compelling package to sponsors and contract research organizations (CROs) when it comes to conducting industry sponsored research (ISR). Simply put, a very strong emphasis on patient safety and bene t is combined with a well-developed and equipped healthcare system that is manned by well-trained, highly qualified and English literate medical professionals. As icing on the cake, Malaysia’s multi-ethnic population provides sponsors and CROs with access to genetic diversity while the costs of conducting clinical trials are very competitive when compared to neighbouring countries. In 2017, Malaysia was awarded, for the third consecutive year, as the top four best healthcare provider in the world by International Living-Annual Global Retirement Index.
The long-term focus by the Malaysian Government is to make Malaysia a significant global player in clinical research and this is made possible through the establishment of Clinical Research Malaysia (CRM). CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support for quality studies. As these studies unfold, CRM works together with its partners to create an impetus in delivering better services to its end clients, while at the same time creating high skilled job opportunities.